ERBB2 and breast carcinoma: Most breast cancer patients with FGFR1 amplification showed moderate differentiation (G2, 69.7%) and a luminal subtype with positive hormone receptor status and predominantly HER2- negative status (ER+, 90.9%; PR+, 78.8%; HER2+, 9.1%).